Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia
Earl Sands, Alan Kivitz, Wesley DeHaan, Sheldon S Leung, Lloyd Johnston, Takashi Kei Kishimoto, Earl Sands, Alan Kivitz, Wesley DeHaan, Sheldon S Leung, Lloyd Johnston, Takashi Kei Kishimoto
Abstract
Biologic drugs have transformed the standard of care for many diseases. However, many biologics induce the formation of anti-drug antibodies (ADAs), which can compromise their safety and efficacy. Preclinical studies demonstrate that biodegradable nanoparticles-encapsulating rapamycin (ImmTOR), but not free rapamycin, mitigate the immunogenicity of co-administered biologic drugs. Here we report the outcomes from two clinical trials for ImmTOR. In the first ascending dose, open-label study (NCT02464605), pegadricase, an immunogenic, pegylated uricase enzyme derived from Candida utilis, is assessed for safety and tolerability (primary endpoint) as well as activity and immunogenicity (secondary endpoint); in the second single ascending dose Phase 1b trial (NCT02648269) composed of both a double-blind and open-label parts, we evaluate the safety of ImmTOR (primary endpoint) and its ability to prevent the formation of anti-drug antibodies against pegadricase and enhance its pharmacodynamic activity (secondary endpoint) in patients with hyperuricemia. The combination of ImmTOR and pegadricase is well tolerated. ImmTOR inhibits the development of uricase-specific ADAs in a dose-dependent manner, thus enabling sustained enzyme activity and reduction in serum uric acid levels. ImmTOR may thus represent a feasible approach for preventing the formation of ADAs to a broad range of immunogenic biologic therapies.
Conflict of interest statement
E.S., W.D., S.S.L., L.J., and T.K.K are current or former employees and shareholders of Selecta Biosciences.
© 2022. The Author(s).
Figures
References
- Sriranganathan, M. K., Vinik, O., Pardo Pardo, J., Bombardier, C. & Edwards, C. J. Interventions for tophi in gout. Cochrane. Database. Syst. Rev.8, CD010069 (2021).
- Sundy JS, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306:711–720. doi: 10.1001/jama.2011.1617.
- Baraf HS, et al. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Arthritis. Res. Ther. 2013;15:R137. doi: 10.1186/ar4318.
- Mandell BF, Yeo AE, Lipsky PE. Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase. Arthritis. Res. Ther. 2018;20:286. doi: 10.1186/s13075-018-1782-x.
- Araujo EG, et al. Tophus resolution with pegloticase: a prospective dual-energy CT study. RMD. Open. 2015;1:e000075. doi: 10.1136/rmdopen-2015-000075.
- Richette P, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann. Rheum. Dis. 2017;76:29–42. doi: 10.1136/annrheumdis-2016-209707.
- Lipsky PE, et al. Pegloticase immunogenicity: The relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis. Res. Ther. 2014;16:R60. doi: 10.1186/ar4497.
- Kishimoto TK. Development of ImmTOR tolerogenic nanoparticles for the mitigation of anti-drug antibodies. Front. Immunol. 2020;11:969. doi: 10.3389/fimmu.2020.00969.
- Kishimoto TK, et al. Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles. Nat. Nanotechnol. 2016;11:890–899. doi: 10.1038/nnano.2016.135.
- Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: A review of the evidence. Kidney. Int. 2001;59:3–16. doi: 10.1046/j.1523-1755.2001.00460.x.
- Fischer, R., Turnquist, H. R., Taner, T. & Thomson, A. W. Use of rapamycin in the induction of tolerogenic dendritic cells. Handb. Exp. Pharmacol.188, 215–232 (2009).
- Ilyinskii PO, Roy CJ, LePrevost J, Rizzo GL, Kishimoto TK. Enhancement of the tolerogenic phenotype in the liver by ImmTOR nanoparticles. Front. Immunol. 2021;12:637469. doi: 10.3389/fimmu.2021.637469.
- Maldonado RA, et al. Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance. Proc. Natl. Acad. Sci. U S A. 2015;112:E156–165. doi: 10.1073/pnas.1408686111.
- Mazor R, et al. Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity. Proc. Natl. Acad. Sci. U S A. 2018;115:E733–E742. doi: 10.1073/pnas.1717063115.
- LaMothe RA, et al. Tolerogenic nanoparticles induce antigen-specific regulatory T Cells and provide therapeutic efficacy and transferrable tolerance against experimental autoimmune encephalomyelitis. Front. Immunol. 2018;9:281. doi: 10.3389/fimmu.2018.00281.
- Meliani A, et al. Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration. Nat. Commun. 2018;9:4098. doi: 10.1038/s41467-018-06621-3.
- Boers-Doets CB, et al. Mammalian target of rapamycin inhibitor-associated stomatitis. Future. Oncol. 2013;9:1883–1892. doi: 10.2217/fon.13.141.
- Guttmann A, Krasnokutsky S, Pillinger MH, Berhanu A. Pegloticase in gout treatment - safety issues, latest evidence and clinical considerations. Ther. Adv. Drug. Saf. 2017;8:379–388. doi: 10.1177/2042098617727714.
- Sundy JS, et al. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis. Rheum. 2007;56:1021–1028. doi: 10.1002/art.22403.
- Mahlangu JN, et al. Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity. J. Thromb. Haemost. 2015;13:1989–1998. doi: 10.1111/jth.13141.
- Ridker PM, et al. Lipid-reduction variability and antidrug-antibody formation with Bococizumab. N. Engl. J. Med. 2017;376:1517–1526. doi: 10.1056/NEJMoa1614062.
- Liao K, et al. Characterization of the robust humoral immune response to GSK2618960, a humanized anti-IL-7 receptor monoclonal antibody, observed in healthy subjects in a Phase 1 study. PLoS. One. 2021;16:e0249049. doi: 10.1371/journal.pone.0249049.
- Herold, K. C. et al. Immunomodulatory activity of humanized anti-IL-7R monoclonal antibody RN168 in subjects with type 1 diabetes. JCI. Insight.4, e126054 (2019).
- Li J, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001;98:3241–3248. doi: 10.1182/blood.V98.12.3241.
- Parenky A, et al. New FDA draft guidance on immunogenicity. AAPS. J. 2014;16:499–503. doi: 10.1208/s12248-014-9587-6.
- Pegvaliase-pqpz BLA approval letter .
- Zhang AH, Rossi RJ, Yoon J, Wang H, Scott DW. Tolerogenic nanoparticles to induce immunologic tolerance: Prevention and reversal of FVIII inhibitor formation. Cell. Immunol. 2016;301:74–81. doi: 10.1016/j.cellimm.2015.11.004.
- Lim HH, et al. A pilot study on using rapamycin-carrying synthetic vaccine particles (SVP) in conjunction with enzyme replacement therapy to induce immune tolerance in Pompe disease. Mol .Genet. Metab. Rep. 2017;13:18–22. doi: 10.1016/j.ymgmr.2017.03.005.
- Ilyinskii, P. O. et al. Enhancement of liver-directed transgene expression at initial and repeat doses of AAV vectors admixed with ImmTOR nanoparticles. Sci. Adv.7, eabd0321 (2021).
- Bomalaski JS, Holtsberg FW, Ensor CM, Clark MA. Uricase formulated with polyethylene glycol (uricase-PEG 20): Biochemical rationale and preclinical studies. J. Rheumatol. 2002;29:1942–1949.
Source: PubMed